Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Van Hasselt, J G Coen ^a   Allegaert, Karel ^b,c   Van Calsteren, Kristel ^b,c   Beijnen, Jos H ^a,d   Schellens, Jan H M ^a,d   Huitema, Alwin D R ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAZOLIN; CREATININE;

ADULT; ARTICLE; CHEMICAL MODEL; CONTROLLED STUDY; CREATININE CLEARANCE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; FEMALE; GESTATIONAL AGE; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MATHEMATICAL MODEL; PREGNANCY; PREGNANT WOMAN; PROTEIN BINDING; YOUNG ADULT; BIOLOGICAL MODEL; DEMOGRAPHY; EMPIRICAL RESEARCH; METABOLISM; NONLINEAR SYSTEM; TIME;

ADULT; CEFAZOLIN; CREATININE; DEMOGRAPHY; EMPIRICAL RESEARCH; FEMALE; HUMANS; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; PREGNANCY; TIME FACTORS; YOUNG ADULT;

EID: 84896874378     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/897216     Document Type: Article

References (18)

1. Dollery C., Therapeutic Drugs 1999 2nd London, UK Churchill Livingstone
2. Vella-Brincat J. W. A., Begg E. J., Kirkpatrick C. M. J., Zhang M., Chambers S. T., Gallagher K., Protein binding of cefazolin is saturable in vivo both between and within patients. British Journal of Clinical Pharmacology 2007 63 6 753 757 2-s2.0-34248577631 10.1111/j.1365-2125.2006.02827.x
3. Allegaert K., Van Mieghem T., Verbesselt R., Vanhole C., Devlieger R., Cossey V., Deprest J., De Hoon J., Cefazolin plasma protein binding saturability during pregnancy. Methods and Findings in Experimental and Clinical Pharmacology 2009 31 1 25 28 2-s2.0-67649207570 10.1358/mf.2009.31.1.1346611
4. Steckelberg J. M., Rouse M. S., Tallan B. M., Osmon D. R., Henry N. K., Wilson W. R., Relative efficacies of broad-spectrum cephalosporins for treatment of methicillin-susceptible Staphylococcus aureus experimental infective endocarditis. Antimicrobial Agents and Chemotherapy 1993 37 3 554 558 2-s2.0-0027483143 10.1128/AAC.37.3.554
5. Gyssens I. C., Preventing postoperative infections. Drugs 1999 57 2 175 185 2-s2.0-0033044675 10.2165/00003495-199957020-00004
6. Howard G. W., Begg E. J., Chambers S. T., Brincat J. V., Zhang M., Kirkpatrick C. M. J., Free and total cefazolin plasma and interstitial fluid concentrations at steady state during continuous infusion. Journal of Antimicrobial Chemotherapy 2002 50 3 429 432 2-s2.0-0036733471 10.1093/jac/dkf129
7. Anderson G. D., Pregnancy-induced changes in pharmacokinetics. Clinical Pharmacokinetics 2005 44 10 989 1008 2-s2.0-25144516296 10.2165/00003088- 200544100-00001
8. Van Hasselt J. G. C., Andrew M. A., Hebert M. F., Tarning J., Vicini P., Mattison D. R., The status of pharmacometrics in pregnancy: highlights from the 3rd American conference on pharmacometrics. British Journal of Clinical Pharmacology 2012 74 6 932 939 10.1111/j.1365-2125.2012.04280.x
9. Allegaert K., van Mieghem T., Verbesselt R., de Hoon J., Rayyan M., Devlieger R., Deprest J., Anderson B. J., Cefazolin pharmacokinetics in maternal plasma and amniotic fluid during pregnancy. American Journal of Obstetrics and Gynecology 2008 200 2 170.e1 170.e7 2-s2.0-58749088537 10.1016/j.ajog.2008.08. 067
10. Fiore Mitchell T., Pearlman M. D., Chapman R. L., Bhatt-Mehta V., Faix R. G., Maternal and transplacental pharmacokinetics of cefazolin. Obstetrics and Gynecology 2001 98 6 1075 1079 2-s2.0-0035690578 10.1016/S0029-7844(01)01629-5
11. Brown C. E. L., Christmas J. T., Bawdon R. E., Placental transfer of cefazolin and piperacillin in pregnancies remote from term complicated by Rh isoimmunization. American Journal of Obstetrics and Gynecology 1990 163 3 938 943 2-s2.0-0025039063 10.1016/0002-9378(90)91101-H
12. Cockcroft D. W., Gault M. H., Prediction of creatinine clearance from serum creatinine. Nephron 1976 16 1 31 41 2-s2.0-0016916438 10.1159/000180580
13. van Hasselt J. G. C., Green B., Morrish G. A., Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women. Pharmaceutical Research 2012 29 6 1609 1617 2-s2.0-84855600509 10.1007/s11095-012-0671-2
14. Davison J. M., Hytten F. E., Glomerular filtration during and after pregnancy. BJOG: An International Journal of Obstetrics & Gynaecology 1974 81 8 588 595 2-s2.0-0016162384 10.1111/j.1471-0528.1974.tb00522.x
15. Lebaudy C., Hulot J. S., Amoura Z., Costedoat-Chalumeau N., Serreau R., Ankri A., Conard J., Cornet A., Dommergues M., Piette J. C., Lechat P., Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clinical Pharmacology and Therapeutics 2008 84 3 370 377 2-s2.0-49949084605 10.1038/clpt.2008.73
16. Beal S. L., Boeckman A. J., Sheiner L. B., NONMEM User Guides 1988 San Francisco, Calif, USA
17. Lo Y.-L., Van Hasselt J. G. C., Heng S.-C., Lim C.-T., Lee T.-C., Charles B. G., Population pharmacokinetics of vancomycin in premature malaysian neonates: identification of predictors for dosing determination. Antimicrobial Agents and Chemotherapy 2010 54 6 2626 2632 2-s2.0-77952659134 10.1128/AAC.01370-09
18. Nielsen E. I., Cars O., Friberg L. E., Pharmacokinetic/Pharmacodynamic (PK/PD) indices of antibiotics predicted by a semimechanistic PKPD model: a step toward model-based dose optimization. Antimicrobial Agents and Chemotherapy 2011 55 10 4619 4630 2-s2.0-80052828741 10.1128/AAC.00182-11